Study wrapper · #1200
Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.
Editor's note
A genuinely new side-effect signal from a very large matched records database, and one that fits plausibly with known GLP-1 effects on reflux and delayed gastric emptying. The design is retrospective and diagnosis-code-based, so confounding and detection bias — people on these drugs see doctors more often — could account for some of the effect. The tirzepatide null result is intriguing but should not be over-read; it may reflect the shorter time this drug has been on the market. One to note for readers tracking the fuller side-effect picture as these medications scale to tens of millions of users.
Plain-language abstract
Researchers looked at health records from over 600,000 adults with obesity taking GLP-1 medications and compared them with millions of similar adults not taking them. Within six months of starting, the medication group had modestly higher rates of throat and voice complaints, especially cough, a lump-in-the-throat sensation, and voice changes. The elevated odds showed up for semaglutide and several older GLP-1 drugs, but notably not for tirzepatide. The absolute increase for any individual was small, and this kind of records-based study can show an association but cannot prove the medications caused the symptoms.